NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $3.25 +0.08 (+2.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.12▼$3.3950-Day Range$2.44▼$3.2552-Week Range$0.97▼$4.00Volume149,591 shsAverage Volume254,669 shsMarket Capitalization$228.90 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Trevi Therapeutics alerts: Email Address Trevi Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.2% Upside$8.00 Price TargetShort InterestBearish1.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingSelling Shares$232,454 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.42) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector486th out of 936 stocksPharmaceutical Preparations Industry224th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Trevi Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.80% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 32.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVI. Previous Next 2.9 News and Social Media Coverage News SentimentTrevi Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Trevi Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for TRVI on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,454.00 in company stock.Percentage Held by Insiders24.37% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.42) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -9.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -9.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Trevi Therapeutics Stock (NASDAQ:TRVI)Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Read More TRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVI Stock News HeadlinesJuly 23, 2024 | msn.comWhat happens to all the money thrown in Rome's Trevi Fountain?July 2, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming Investor and Healthcare EventsJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 13, 2024 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call TranscriptMay 12, 2024 | uk.investing.comEarnings call: Trevi Therapeutics reports progress in clinical trialsMay 12, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 9, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming ConferencesJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)May 8, 2024 | finance.yahoo.comQ1 2024 Trevi Therapeutics Inc Earnings CallMay 7, 2024 | investorplace.comTRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Q1 2024 Financial Results: A Detailed AnalysisMay 7, 2024 | prnewswire.comTrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 1, 2024 | yahoo.comGloria Trevi Clears First Hurdle for Lawsuit Claiming She Was Main Victim of Sex AbuseMay 1, 2024 | prnewswire.comTrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024April 9, 2024 | finance.yahoo.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 9, 2024 | prnewswire.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceSee More Headlines Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRVI CUSIPN/A CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+146.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.54% Return on Assets-36.80% Debt Debt-to-Equity RatioN/A Current Ratio14.55 Quick Ratio14.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book2.52Miscellaneous Outstanding Shares70,430,000Free Float53,270,000Market Cap$228.90 million OptionableOptionable Beta1.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Jennifer L. Good (Age 59)Co-Founder, CEO, President & Director Comp: $781.85kDr. Thomas R. Sciascia M.D. (Age 71)Co-Founder & Chief Science Officer Comp: $530.48kDr. David J. Clark A.F.P.M. (Age 59)M.D., M.R.C.P., Chief Medical Officer Comp: $325.39kMs. Lisa Delfini (Age 54)Chief Financial Officer Mr. Christopher Galletta (Age 46)Controller & Chief Accounting Officer Katie McManusCommunications ManagerMr. Farrell Simon Pharm.D.Chief Commercial OfficerMs. Danine Summers (Age 66)Vice President of Medical Affairs More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDAProteostasis TherapeuticsNASDAQ:PTIVYNE TherapeuticsNASDAQ:VYNECara TherapeuticsNASDAQ:CARACureVacNASDAQ:CVACView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 49,884 shares on 7/26/2024Ownership: 0.253%Rosalind Advisors Inc.Bought 465,561 shares on 7/12/2024Ownership: 1.976%Opaleye Management Inc.Bought 110,000 shares on 5/29/2024Ownership: 3.756%Thomas SciasciaSold 53,368 sharesTotal: $136,088.40 ($2.55/share)Lisa DelfiniSold 4,350 sharesTotal: $11,484.00 ($2.64/share)View All Insider TransactionsView All Institutional Transactions TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $1.34 on January 1st, 2024. Since then, TRVI shares have increased by 142.5% and is now trading at $3.25. View the best growth stocks for 2024 here. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.02. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' top institutional shareholders include Rosalind Advisors Inc. (1.98%) and Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Tpg Gp A, Llc, Thomas Sciascia, Jennifer L Good and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE) and Akero Therapeutics (AKRO). This page (NASDAQ:TRVI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
